Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Purpose
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Conditions
- Cancer
- Liver Cirrhosis
- Chronic Hepatitis
- Hepatitis B
- Hepatitis C
- Diabetes
- COPD
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- 1.1 Age 18 years or older. 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .
Exclusion Criteria
- 2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded. 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Recruiting Locations
Allina Health, Virginia Piper Cancer Institute
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
Virginia Piper Cancer Institute Mercy Hospital-Unity Campus
Fridley, Minnesota 55432
Fridley, Minnesota 55432
VPCI Oncology Research
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55407
Methodist LeBonheur Healthcare
Memphis, Tennessee 38104
Memphis, Tennessee 38104
More Details
- NCT ID
- NCT05181826
- Status
- Recruiting
- Sponsor
- Helio Genomics
Detailed Description
Whole blood, plasma, and/or serum specimens will be collected from patients with active cancer, patients in cancer remission, patients diagnosed with benign disease, and healthy volunteers. These blood samples will be used to perform various studies to determine the utility of select DNA methylation markers for cancer diagnostic or prognostic indications.